Acarbose: A review of US clinical experience

Clinical Therapeutics

Volumn 19, Issue 1, 1997, Pages 16-26

  Coniff, Robert ^a   Krol, Alice ^a  

^a BAYER CORPORATION   (United States)

Author keywords

acarbose; glycated hemoglobin; non insulin dependent diabetes mellitus; postprandial glucose; glucosidase inhibition

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; SULFONYLUREA DERIVATIVE;

CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET; DRUG EFFICACY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; REVIEW; UNITED STATES;

EID: 0030935018     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80069-0     Document Type: Article

References (17)

1. El-Kebbi IM, Bacha GA, Ziemer DC, et al. Diabetes in urban African Americans. V. Use of discussion groups to identify barriers to dietary therapy among low-income individuals with non-insulin-dependent diabetes mellitus. Diabetes Educ. 1996;22:488-492.
2. Riley MD, Blizzard L. Comparative validity of a food frequency questionnaire for adults with IDDM. Diabetes Care. 1995;18:1249-1254.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993;329:977-986.
4. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703-1720.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 1995;113:36-51.
6. Melander A, Lebovitz HE, Faber OK. Sulfonylureas. Why, which, and how? Diabetes Care. 1990;13(Suppl 3):18-25.
7. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 1994;11:223-241.
8. Bischoff H. Pharmacology of α-glucosidase inhibition. Eur J Clin Invest. 1994; 24(Suppl 3):3-10.
9. Toeller M. Alpha-glucosidase inhibitors in diabetes: Efficacy in NIDDM subjects. Eur J Clin Invest. 1994;24(Suppl 3): 31-35.
10. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care. 1995;18:817-824.
11. Data on file. Bayer Corporation, Pharmaceutical Division, West Haven, Connecticut, 1989.
12. 1c in the Diabetes Control and Complications Trial (DCCT). Clin Chem. 1987; 33:2267-2271.
13. Coniff RF, Shapiro JA, Seaton TB. Longterm efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1994;154:2442-2448.
14. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamideplus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995;98: 443-451.
15. Hanefeld M. Acarbose efficacy review. Pract Diabetes. 1993;10(Suppl 6):S21-S27.
16. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care. 1993;16: 1517-1520.
17. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ. 1995;310: 83-88.